Jazz Pharmaceuticals (JAZZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$246.81-0.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · JAZZ
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $247 JAZZ trades at 9.9× p/e, below its 16× p/e peer median. Our $294 fair value sits above the price. It's a high-confidence read. Analysts target $229–$322. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $285.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $245.95 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $888.38 | — | — | Hist. CAGR | high |
| graham number | 12M | $196.72 | — | — | TTM | high |
| Peer P/FCF | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$229.00 – $322.00 (median $285.00) · 29 analysts · as of 2026-08-28
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $314.03 |
| 14.1 |
| 22.22 |
| TTM |
| high |
| Peer P/E | 12M | $278.88 | 10.9 | 25.57 | ntm analyst | high |
| Peer P/S | 12M | $192.64 | 2.9 | 66.30 | TTM | high |
| PEG | 12M | $72.82 | 2.9 | 24.86 | TTM | high |
| residual income | 12M | $144.54 | — | — | TTM | high |
| Own P/E history | 12M | $277.06 | 11.1 | 24.86 | TTM | high |
| triangulated | 12M | $407.61 | 16.1 | 25.37 | Triangulated | high |
| Peer P/FCF | 3Y | $477.61 | 14.1 | 33.80 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $289.56 | 10.9 | 26.54 | Analyst | medium |
| Peer P/S | 3Y | $214.81 | 2.9 | 73.93 | guidance | medium |
| PEG | 3Y | $77.75 | 2.9 | 26.54 | Analyst | medium |
| Own P/E history | 3Y | $295.83 | 11.1 | 26.54 | Analyst | medium |
| Peer P/FCF | 5Y | $631.63 | 14.1 | 44.70 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $298.92 | 10.9 | 27.40 | Analyst | high |
| Peer P/S | 5Y | $221.74 | 2.9 | 76.32 | guidance | high |
| PEG | 5Y | $80.27 | 2.9 | 27.40 | Analyst | high |
| Own P/E history | 5Y | $305.39 | 11.1 | 27.40 | Analyst | high |